期刊文献+

人源抗HBsAg抗体Fd段和L链高效表达菌株的筛选 被引量:2

The efficient expression of anti-HBsAg human Fd and L chain in E.coli
下载PDF
导出
摘要 目的 :选用高效表达载体分别高效表达人源抗HBsAg抗体的Fd段和L链 ,经包涵体纯化和变性复性使Fd段和L链之间形成二硫键 ,最终制备有活性、高产量的人源抗HBsAg基因工程抗体Fab。方法 :用PCR法从可溶性表达重组质粒抗HBsAgFadComb3扩增Fd段和L链后分别构建高效表达载体PQE32 Fd和PQE32 L ,并分别导入大肠杆菌M15中进行表达 ,用SDS PAGE筛选出高效表达克隆。结果 :SDS PAGE筛选的高效表达克隆M15 PQE32 Fd和M15 PQE32 L经IPTG诱导后以包涵体形式表达 ,其表达量很高。从高效表达克隆重新扩增Fd段和L链后进行测序鉴定发现所得的序列与已报道的抗HBsAg抗体Fab基因吻合率为 97%。结论 :虽然已有表达可溶性人源抗HBsAg基因工程抗体Fab的报道 ,但因其表达量低而不能实际应用。筛选出高效表达人源抗HBsAg抗体Fd段和L链的克隆 ,因为包涵体形式表达需经变性复性 ,虽然变性复性后其产量会受影响 ,但因表达量很高 ,所以还是有很高的实际应用价值。其包涵体变性复性条件仍需进一步探讨。 Objective:Choosing efficient expression vector express anti HBsAg Fd and L chain in E.coli to produce anti HBsAg human Fab.Purificating inclusion bodies to denaturating and refolding the protein.Methods:Expression vector of PQE32 Fd、PQE32 L was constructed and transformed into E.coli strain M15,efficient expression clone was screened by SDS PAGE.Results:After induced by IPTG,M15 PQE32 Fd、M15 PQE32 L expressed insoluble recombinant protein in inclusion bodies.The Fd、L chain gene sequence conform with that reported in NCBI BLAST.Conclusion:The M15 PQE32 expression system is stable and efficient for expressing anti HBs human Fd、L chain.The denaturation and protein refolding of the anti HBsAg Fab expressed in inclusion bodies need to be studied further.
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2001年第6期289-291,共3页 Chinese Journal of Immunology
关键词 HBSAG 人源抗体Fab 高效表达 乙肝 抗体工程技术 HBsAg Human Fab Efficient expression
  • 相关文献

参考文献3

二级参考文献3

共引文献65

同被引文献22

  • 1纪晋文,代丽萍,段广才,郗园林.幽门螺杆菌HspA-UreB融合蛋白包涵体的纯化及活性鉴定[J].吉林大学学报(医学版),2005,31(2):256-258. 被引量:2
  • 2李晓静,张豪,付学奇,李彦英,陈璟,李玉玲,方宏清,陈惠鹏.炭疽杆菌噬菌体裂解酶基因在大肠杆菌中的表达及鉴定[J].生物工程学报,2005,21(2):216-219. 被引量:7
  • 3张龙翔,张庭芳,汪家政.蛋白质手册.北京:科学出版社,2000:42-46.
  • 4Koller T, Nelson D, Nakata M, et al. PlyC, a novel bacteriophage lysin for compartment-dependent proteomics of group A streptococci. Proteomics, 2008, 8(1): 140-148.
  • 5Lopez R, Garcia E, Garcia E Enzymes for anti-infective therapy: phage lysins. Drug Discov Today: Therap Strat, 2004, 1(4): 469-474.
  • 6Schrag S J, Mcgee L, Whitney CG, et al. Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin. Antimicrob Agents Chemother, 2004, 48(8): 3016-3023.
  • 7Fischetti VA. Bacteriophage lytic enzyme: novel antiinfectives. Trends Microbiol, 2005, 13(10): 491-496.
  • 8Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lyric enzyme. Proc Natl Acad Sci USA, 2001, 98(7): 4107-4112.
  • 9Fischetti VA, Vincent, Loomis, et al. Throat lozenge for the treatment of Streptococcus group A: US patent, 7,232,576. 2007-06-19.
  • 10Jacobs MR. Streptococcus pneumoniae: epidemiology and patterns of resistance. Am J Med, 2004, 117(3): 3-15.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部